
Oncology NEWS International
- Oncology NEWS International Vol 15 No 10
- Volume 15
- Issue 10
Interim Results for MediGene's Oncolytic Virus NV1020
MediGene AG has announced that the interim analysis of a phase I/II trial of its oncolytic herpes simplex virus NV1020 has shown efficacy for the treatment of liver metastases in patients with colorectal cancer. Therefore, the trial will continue as scheduled, with the maximum dosage of the virus. The agent is delivered to the liver at weekly intervals through the hepatic artery. All patients receiving the maximum dosage demonstrated either disease stabilization or a clear regression of liver metastases, the company said in a press release, adding that some patients showed regressing metastases in other organs as well.
MARTINSRIED, GermanyMediGene AG has announced that the interim analysis of a phase I/II trial of its oncolytic herpes simplex virus NV1020 has shown efficacy for the treatment of liver metastases in patients with colorectal cancer. Therefore, the trial will continue as scheduled, with the maximum dosage of the virus. The agent is delivered to the liver at weekly intervals through the hepatic artery. All patients receiving the maximum dosage demonstrated either disease stabilization or a clear regression of liver metastases, the company said in a press release, adding that some patients showed regressing metastases in other organs as well.
Articles in this issue
almost 20 years ago
Recombinant MAGE-A3 Cancer Immunotherapy Promisingalmost 20 years ago
WHI Calcium/Vit D Trial:almost 20 years ago
Negative Lymph Nodes Predict Survival in Stage III Colon Caalmost 20 years ago
Oophorectomy Value Varies by BRCA Typealmost 20 years ago
FDA Approves Vectibix for Metastatic Colon Caalmost 20 years ago
Brain Cancer Cells Attract Stem Cells for Angiogenesisalmost 20 years ago
NCCN Presents Hematologic Ca Congressalmost 20 years ago
GSK Files NDA for Tykerb for Advanced Breast Cancer Rxalmost 20 years ago
Armstrong to Run New York City Marathon

























































